Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN -6.28%24 3-1 Month Momentum % is -69.18% as of Sep. 03, 2026. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 98.82% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-03), Anbio Biotechnology's 3-1 Month Momentum % is -69.18%.
The industry rank for Anbio Biotechnology's 3-1 Month Momentum % or its related term are showing as below:
NNNN's 3-1 Month Momentum % is ranked worse than 98.82% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -4.9
vs NNNN: -69.18
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Anbio Biotechnology 3-1 Month Momentum % Related Terms
NNNN vs SMTI, EMBC, OSUR: 3-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a 3-1 Month Momentum % of -69.18% as of Sep. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Anbio Biotechnology and its competitors. According to the industry distribution chart, Anbio Biotechnology ranks #839 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 98.8%.
Is Anbio Biotechnology's 3-1 Month Momentum % too high?
Anbio Biotechnology's current 3-1 Month Momentum % is -69.18%. Based on the distribution chart, Anbio Biotechnology ranks #839 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's 3-1 Month Momentum % compare to SMTI and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #839 out of 849 companies for 3-1 Month Momentum %. This places Anbio Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current 3-1 Month Momentum % is -69.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current 3-1 Month Momentum % of -69.18%. The current 3-1 Month Momentum % is -69.18%. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current 3-1 Month Momentum % is -69.18% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
